To The Moon

U.S. stocks rose Friday ahead of Federal Reserve Chair Jerome Powell’s speech at Jackson Hole on Friday. Investors will be seeking clues on the path forward for monetary policy.Investors are looking...

NVIDIA (NASDAQ:NVDA) reported quarterly earnings of $6.12 per share which beat the analyst consensus estimate of $5.59 by 9.48 percent. The company reported quarterly sales of $26.044 billion which beat the analyst

Attention is on AI darling’s annual GTC conference next weekNvidia often uses event to announce products and expectationsJen-Hsun HuangNvidia Corp.’s annual artificial intelligence conference is just

U.S. stocks ended sharply up on Thursday, with the S&P 500 approaching record highs as AI optimism drove gains in Nvidia and other chipmakers.The S&P 500 climbed 0.88% to end the session at 4,780.94 p

NVIDIA (NASDAQ:NVDA) reported quarterly earnings of $4.02 per share which beat the analyst consensus estimate of $3.36 by 19.64 percent. This is a 593.1 percent increase over earnings of $0.58 per share from the same

TSMC investors see signs of a turnaround in sales -- and maybe profits as well.

Bagsvrd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars.Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease . Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more blood pressure-lowering treatments.“We look forward to adding ocedurenone to our pipeline as it will complement our current development programmes in cardiovascular disease and chronic kidney disease,” said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs at Novo Nordisk. “This deal is closely al

The healthcare sector is a recession-proof one with these four stocks dishing out dividends.